Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 20/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3107744 | 0.96 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL3102518 | 0.91 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL3105317 | 0.91 | CRHR1 (0.87) | CRHR1 | |
| Hydrochloric Acid SCHEMBL3110367 | 0.90 | CRHR1 (0.98) | CRHR1 | |
| SCHEMBL1614366 | 0.88 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL1614465 | 0.86 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL3101044 | 0.86 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL1613859 | 0.86 | CRHR1 (0.91) | CRHR1 | |
| Bromide SCHEMBL3238098 | 0.86 | CRHR1 (0.98) | CRHR1 | |
| SCHEMBL3104922 | 0.86 | CRHR1 (0.95) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431603-B2 | 3-phenylpyrazolo[5,1-b]thiazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-04-30 | — | — | US | disclosed |
| EP-2266990-A1 | 3-PHENYLPYRAZOLOÝ5,1-b¨THIAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2010-12-29 | — | — | EP | disclosed |
| US-20090259049-A1 | 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUNDS | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090259049-A1 | 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUNDS | CRHR1, AGTR1, CRHR2 | CRHR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.